Literature DB >> 10515687

Binding studies of tear lipocalin: the role of the conserved tryptophan in maintaining structure, stability and ligand affinity.

O K Gasymov1, A R Abduragimov, T N Yusifov, B J Glasgow.   

Abstract

The principal lipid binding protein in tears, tear lipocalin (TL), binds acid and the fluorescent fatty acid analogs, DAUDA and 16-AP at one site TL compete for this binding site. A fluorescent competitive binding assay revealed that apo-TL has a high affinity for phospholipids and stearic acid (Ki) of 1.2 microM and 1.3 microM, respectively, and much less affinity for cholesterol (Ki) of 15.9 of the hydrocarbon chain. TL binds most strongly the least soluble lipids permitting these lipids to exceed their maximum solubility in aqueous solution. These data implicate TL in solubilizing and transporting lipids in the tear film. Phenylalanine, tyrosine and cysteine+ were substituted for TRP 17, the only invariant residue throughout the lipocalin superfamily. Cysteine substitution resulted in some loss os secondary structure, relaxation of aromatic side chain rigidity, decreased binding affinity for DAUDA and destabilization of structure. Mutants of TL, W17Y, and W17F showed a higher binding affinity for DAUDA than wild-type TL. Comparison of the results of the tryptophan 17 substitution in lipocalin with those of tryptophan 19 substitution in beta-lactoglobulin revealed important differences in binding characteristics that reflect the functional heterogeneity within the lipocalin family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515687     DOI: 10.1016/s0167-4838(99)00133-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  39 in total

1.  Resolution of ligand positions by site-directed tryptophan fluorescence in tear lipocalin.

Authors:  O K Gasymov; A R Abduragimov; T N Yusifov; B J Glasgow
Journal:  Protein Sci       Date:  2000-02       Impact factor: 6.725

2.  Excited protein states of human tear lipocalin for low- and high-affinity ligand binding revealed by functional AB loop motion.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  Biophys Chem       Date:  2010-04-09       Impact factor: 2.352

3.  Decreased tear lipocalin concentration in patients with meibomian gland dysfunction.

Authors:  M Yamada; H Mochizuki; M Kawai; K Tsubota; T J Bryce
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

4.  Characterization of fluorescence of ANS-tear lipocalin complex: evidence for multiple-binding modes.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  Photochem Photobiol       Date:  2007 Nov-Dec       Impact factor: 3.421

Review 5.  Lacritin and the tear proteome as natural replacement therapy for dry eye.

Authors:  Roy Karnati; Diane E Laurie; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2013-06-12       Impact factor: 3.467

6.  Effect of short- and long-range interactions on trp rotamer populations determined by site-directed tryptophan fluorescence of tear lipocalin.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  PLoS One       Date:  2013-10-28       Impact factor: 3.240

7.  A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity.

Authors:  Daniel A Breustedt; Lorenz Chatwell; Arne Skerra
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-09-16

8.  Ligand binding complexes in lipocalins: Underestimation of the stoichiometry parameter (n).

Authors:  Ben J Glasgow; Adil R Abduragimov
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2018-07-07       Impact factor: 3.036

9.  A simple model-free method for direct assessment of fluorescent ligand binding by linear spectral summation.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  J Fluoresc       Date:  2013-09-18       Impact factor: 2.217

10.  Human tear lipocalin exhibits antimicrobial activity by scavenging microbial siderophores.

Authors:  Maria Fluckinger; Hubertus Haas; Petra Merschak; Ben J Glasgow; Bernhard Redl
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.